Researchers find low link between hair loss and weight-loss drugs

While GLP-1 medications are effective for weight loss and diabetes management, new research suggests a potential side effect: hair loss.

Three recent studies indicate that the risk of experiencing hair loss while taking GLP-1 drugs, such as semaglutide (Wegovy, Ozempic) and tirzepatide (Zepbound, Mounjaro), is low but higher than with other types of diabetes medication. The research, published in journals like The BMJ and the Journal of the American Academy of Dermatology, analyzed data from numerous users worldwide.

One study found that after two or more years of GLP-1 treatment, the likelihood of hair loss was 37 percent higher compared to users of SGLT-2 inhibitors and 68 percent higher than with DPP-4 inhibitors. Another study indicated a significantly higher risk of hair loss with GLP-1 medications compared to metformin, a common diabetes drug.

Furthermore, a third study, which is still undergoing peer review, suggested a slightly greater likelihood of hair loss with tirzepatide compared to semaglutide. However, researchers noted that the difference was small, and the risk persisted regardless of the amount of weight lost or the dosage taken. This suggests that factors other than weight loss itself might contribute to hair loss.

Importantly, the studies emphasize that hair loss associated with these medications often occurs concurrently with weight loss and is generally considered temporary. While the findings highlight an increased risk, they do not negate the significant benefits these drugs offer for managing diabetes and obesity.